stockportfolio.pro
Stocks / MRNA vs ONC
MRNA vs ONC
Moderna, Inc. and BeOne Medicines AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
ONC is the larger company ($27.0B vs $24.5B). On the fundamentals, ONC grows revenue faster (76.8% vs 19.3%); ONC earns a higher net margin (5.4% vs -145.2%); ONC has the stronger return on equity (6.6% vs -32.6%). Full numbers below — the stronger figure on each row is in green.
| Moderna, Inc. (MRNA) | BeOne Medicines AG (ONC) | |
|---|---|---|
| Market cap | $24.5B | $27.0B |
| Revenue (latest FY) | $1.94B | $5.34B |
| Net income (latest FY) | $-2.82B | $286.93M |
| Revenue growth (5y CAGR) | 19.3% | 76.8% |
| Net margin | -145.2% | 5.4% |
| Return on equity | -32.6% | 6.6% |
| P/E ratio | — | 58.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full MRNA vs ONC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MRNA's full financials → Open ONC's full financials →More comparisons
Frequently asked questions
Which is bigger, MRNA or ONC?
BeOne Medicines AG is larger by market capitalization — $27.0B versus $24.5B.
Which grows faster, MRNA or ONC?
Over the last five fiscal years, BeOne Medicines AG grew revenue faster — 76.8%/yr versus 19.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
MRNA fundamentals → · ONC fundamentals → · All 1,500+ companies → · Free screener →